Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study

NCT07550452 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis (AD)

Interventions

DRUG: Ivarmacitinib Sulfate Tablets

Sponsor

Peking University People's Hospital